Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity.
Doxorubicin intercalates into DNA, causes double-strand breaks, and leads to apoptotic death. Limitations to the efficacy and therapeutic index of doxorubicin include poor tumor selectivity, high systemic toxicity, and the development of resistance, especially p-glycoprotein (p-gp)-mediated. We chemically coupled doxorubicin to a monoclonal antibody directed to the insulin-like growth factor-1 receptor, a receptor highly overexpressed in most tumors and validated as a tumor target. The prodrug conjugate bounded to tumor cells selectively, and accumulated efficiently and only in receptor-expressing cells. The conjugate was processed to release free doxorubicin inside target cells leading to selective toxicity, had >200-fold improved therapeutic index, and in vivo reduced tumor load with no systemic toxicity. Importantly, the prodrug conjugate is not subject to p-gp efflux and can bypass resistance in vivo. Our studies define a strategy to develop improved and more selective anticancer agents.